Signals
4Pulmonary embolism management restructures around catheter-directed therapy and risk stratification
DOAC first-line maturity, catheter-directed thrombolysis and mechanical thrombectomy growth, and structured pulmonary embolism response team (PERT) infrastructure are reshaping pulmonary embolism care.
Lipid management therapy widens past statins and PCSK9 monoclonals
Inclisiran maturity, bempedoic acid, lepodisiran and emerging oral PCSK9 programs, and ANGPTL3-targeted therapy are restructuring lipid management.
Type 1 diabetes therapy reshapes around disease modification and automation
Teplizumab disease modification, automated insulin delivery system maturity, and emerging beta-cell replacement programs are restructuring T1D management.
GLP-1 supply normalisation is shifting the prescribing decision back to clinical fit
Manufacturing capacity for the GLP-1 class has substantially normalised after two years of supply constraint. The prescribing decision is moving back from availability-driven to clinical-fit-driven, and the commercial dynamics are shifting accordingly.
Snapshots
2Lipid management therapy reference (2026)
Reference snapshot of lipid management therapy across foundational, add-on, and emerging tiers.
Type 1 diabetes therapy reference (2026)
Reference snapshot of T1D therapy across insulin delivery, disease modification, and beta-cell replacement.